Blossom PharmaceuticalsApril 11, 2025

FDA 483 - Blossom Pharmaceuticals - April 11, 2025

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Blossom Pharmaceuticals

Record Details

Blossom Pharmaceuticals, an OTC drug manufacturer in Bardez, Goa, India, received a Form 483 for significant GMP deficiencies. The inspection revealed systemic failures in data integrity, process and cleaning validation, equipment maintenance, laboratory controls, environmental conditions, quality unit oversight, and personnel training. These issues indicate a profound lack of control over manufacturing processes and product quality.

Company: Blossom Pharmaceuticals
Inspection Date: April 11, 2025
Product Type: Drugs
Office: Office of Inspections and Investigations
Person: Kellia N. Hicks (Investigator)

Open in Dashboard

ID · 0d392295-6aa6-4e44-ac26-1d7eb1438b92